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Abstract
The proteins of the Inhibitor of Growth (ING) family are involved in multiple cellular functions such as cell cycle regulation,
apoptosis, and chromatin remodeling. For ING5, its actual role in growth suppression and the necessary partners are not
known. In a yeast-two-hybrid approach with human bone marrow derived cDNA, we identified ING5 as well as several other
proteins as interaction partners of Inhibitor of cyclin A1 (INCA1) that we previously characterized as a novel interaction
partner of cyclin A1/CDK2. ING5 expression in leukemic AML blasts was severely reduced compared to normal bone marrow.
In line, ING5 inhibited bone marrow colony formation upon retroviral transduction. However, Inca1
2/2 bone marrow colony
formation was not suppressed by ING5. In murine embryonic fibroblast (MEF) cells from Inca1
+/+ and Inca1
2/2 mice,
overexpression of ING5 suppressed cell proliferation only in the presence of INCA1, while ING5 had no effect in Inca1
2/2
MEFs. ING5 overexpression induced a delay in S-phase progression, which required INCA1. Finally, ING5 overexpression
enhanced Fas-induced apoptosis in Inca1
+/+ MEFs, while Inca1
2/2 MEFs were protected from Fas antibody-induced
apoptosis. Taken together, these results indicate that ING5 is a growth suppressor with suppressed expression in AML
whose functions depend on its interaction with INCA1.
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Introduction
Several ING tumor-suppressor family proteins (ING1-5) have
been discovered during the past decade. The founding member
of the family, ING1, was first identified by subtractive
hybridization between normal human cells and breast cancer
cell lines and was found to be suppressed in cancer cells [1].
Subsequently, ING1 was demonstrated to cooperate with p53 to
induce apoptosis and cellular senescence [2,3]. Since the
discovery of ING1, four additional genes (ING2-5) [4,5,6,7] have
been identified and classified as ING family. All ING proteins
share a highly conserved carboxy-terminal plant homeodomain
(PHD) and are involved in cell cycle regulation, apoptosis and
DNA repair [8,9]. Studies have shown that ING proteins exert
their biological function through their association with specific
molecular partners [10,11,12].
The cell cycle is tightly regulated by different cyclin-CDK
complexes [13,14,15]. An alternative cyclin A, named cyclin A1
[16], associates with CDK2 and is involved in mitosis, meiosis and
malignant diseases [17,18,19,20]. Cyclin A1 is highly expressed in
Acute Myeloid Leukemia (AML) and cyclinA1 overexpression can
induce leukemia. However, the detailed molecular functions of
cyclin A1 remain unclear. In a study aimed to identify interaction
partners and substrates of cyclin A1, INCA1, a novel protein, was
found in a yeast triple-hybrid system to interact with cyclin A1/
CDK2 complex [21]. First functional analyses indicate a growth-
suppressive function through inhibition of CDK2 activity by
INCA1 [21]. Recently, we generated an Inca1 knockout mouse
model to further study the in vivo function of this new protein [22]
(manuscript in preparation). In the present study, by a yeast two-
hybrid approach, we identified several potential interacting
proteins of INCA1 from a bone marrow cDNA library. We
confirmed nine interacting proteins with INCA1 by GST pull-
down assay. ING5 was identified as one of the interacting partners
of INCA1.
ING5 is the new member of ING family which was identified by
computational homology search. Up to now, there are not many
published data about ING5 functions. ING5 has been shown to
physically interact with p300 and p53 in vivo, and ING5
overexpression induces apoptosis in colorectal cancer cells [7].
Recent study finds mutation and downregulation of ING5 mRNA
in oral squamous cell carcinoma, suggesting it as a tumor
suppressor gene [23]. Data from tissue array showed that ING5
translocation from the nucleus to the cytoplasm might be a critical
event for carcinogenesis and tumor progression in human head
and neck squamous cell carcinoma [24,25]. In addition, aberrant
ING5 expression was thought to contribute to pathogenesis,
growth, and invasion of gastric carcinomas and colorectal cancer
[26,27]. The conflicting views of ING5 as a tumor suppressor or
an oncogene are clearly context specific.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21505We found a significant reduction of ING5 expression in AML
patients, which supports a function of ING5 as a tumor
suppressor. We then focused our study on the interaction of
ING5 and INCA1 and the consequence on cell proliferation, cell
cycle and apoptosis. Our results indicate a close dependence of
ING5 on the presence of INCA1 for the regulation of colony
formation, cell proliferation, and apoptosis.
Results
Identification of interacting partners of INCA1
To further address the molecular function of INCA1, we
screened a human bone marrow cDNA library for interacting
proteins of INCA1. Positive clones were confirmed by colony-lift
filter assay and b-galactosidase activity. Sequences from 245
positive clones were analyzed by alignment to the NCBI data bases
and 30 genes from the positive clones were selected for further
investigation. We first confirmed the in vitro interactions by GST
pull-down assay using in vitro transcribed and translated proteins.
As described previously [21], the full length INCA1 cDNA was
cloned, expressed as GST fusion proteins in Escherichia coli and
purified using glutathione-agarose beads. INCA1 GST protein
was incubated with in vitro transcribed and translated TNT system
labeled with [
35S] methionine. Nine known genes interacted with
GST-INCA1(Fig. 1A, Table 1), but not with GST alone,
indicating the specific interactions with INCA1 in vitro.
Figure 1. ING5 interacts with INCA1 in vitro and in vivo. (A) In GST pull-down assays, GST alone or GST fused to INCA1, were incubated with
[
35S] labeled genes which were selected through a yeast two-hybrid (Y2H) screening. Nine known genes were confirmed to interact with INCA1 in
vitro. (B) COS-7 cells were transfected with EGFP-INCA1 and ING5. Immunoprecipitation with anti-EGFP antibody and subsequent Western blotting for
ING5 demonstrated the in vivo interaction of ING5 and INCA1. (C) Immunoprecipitation with anti-ING5 antibody and subsequent Western blotting for
EGFP-INCA1 confirmed the in vivo interaction. (D) Ing5 gene expression was decreased in AML specimens as determined by quantitative real-time RT-
PCR assays based on Taqman technology. AML specimens were obtained at the time of diagnosis (p=0.02).
doi:10.1371/journal.pone.0021505.g001
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Among the nine interacting partners of INCA1, ING5 is a new
member of the candidate tumor-suppressor ING family. Since cyclin
A1 can act as an oncogene, we further focused on the functions of the
interaction between INCA1 and ING5. To further investigate this
interaction in vivo, COS-7 cells were transfected with expression
plasmids for EGFP-INCA1 and ING5. ING5 was immunoprecip-
itated from whole cell lysates with ING5 antibody. The subsequent
Western blotting for EGFP-INCA1 demonstrated the specific
interaction of INCA1 and ING5 in vivo (Fig. 1B). INCA1 was not
precipitated from the cell lysates by nonspecific antibodies (Fig. 1B).
Similarly, ING5 was also precipitated form the cell lysates by anti-
EGFP antibody (Fig. 1C). These data indicated a direct interaction
between INCA1 and ING5 in vitro and at least upon overexpression
also in vivo. Due to the absence of good quality antibodies for
INCA1, no CO-IPs at normal levels in vivo could be performed.
ING5 expression is suppressed in AML patients and ING5
overexpression decreases colony formation efficiency in
the presence of INCA1
We further analyzed Ing5 gene expression at the mRNA level in
AML specimens obtained at the time of primary diagnosis. These
analyses revealed that Ing5 was expressed at significantly lower
levels in AML compared to normal bone marrow (Fig. 1D,
P=0.02), hinting at a potential growth suppressive function of
ING5. We then focused our study onto the functional interactions
of ING5 and INCA1 on cell growth control.
We first performed colony formation assay with primary bone
marrow cells. ING5 expressing or empty vector were retrovirally
transduced into lineage depleted bone marrow cells obtained from
Inca1
+/+ and Inca1
2/2 mice followed by FACS sorting for EGFP
positive cells. Colonies were counted after one week of culture. ING5
overexpression significantly inhibited colony formation in primary
wildtype bone marrow. This is consistent with previous reports in
other cell types that overexpression of ING5 in cancer cells resulted in
reduced colony formation [7]. As a surprise, ING5 overexpression
did not inhibit colony formation of Inca1
2/2 bone marrow cells
(Fig. 2A). These data indicated that ING5 overexpression could
decrease colony formation only in the presence of INCA1.
The anti-proliferative effects of ING5 depend on INCA1
Immortalized MEFs derived from Inca1
+/+ and Inca1
2/2 mice
were retrovirally transduced with empty vector (‘‘control’’) or
ING5. Four cell lines (Inca1
+/+ control, Inca1
+/+ Ing5, Inca1
2/2
control and Inca1
2/2 Ing5) were established after sorting for GFP
positive cells by FACS. ING5 overexpression was confirmed by
Western blot (Fig. 2B).
To determine the effect of ING5 overexpression on cell
proliferation, [
3H]-thymidine incorporation assays were per-
formed. When cultured in medium containing 10% FCS or
0.1% FCS, overexpression of ING5 in Inca1
+/+ MEFs inhibited
cell proliferation compared to wildtype control cells (P,0.01;
Fig. 2C). Overexpressed ING5 did not inhibit the proliferation of
Inca1
2/2 MEFs (Fig. 2C). In Inca1
2/2 MEFs cultured in 0.1%
FCS medium, ING5 overexpression rather increased proliferation
(P,0.05) compared to Inca1
2/2 control cells (Fig. 2C, righthand
panel), showing a similar tendency as observed in colony
formation assay. Taken together, these results indicated that the
growth inhibitory effects of ING5 required INCA1.
INCA1 is important for the activation of p53-responsive
promoter by ING5
ING5 overexpression inhibited cell growth in a p53-dependent
manner by increasing p21/waf1 promoter activity [7]. We
analyzed the effects of INCA1 on the promoter activation function
of ING5. Therefore, we transfected Inca1
2/2 MEFs with
expression vectors containing ING5, INCA1 or both, and we
analyzed the activity of a p53-responsive promoter. ING5
overexpression modestly increased the activity of the p53-
responsive promoter with no statistical significance whereas
INCA1 overexpression had no effect (Fig. 2D). However, when
ING5 and INCA1 were co-transfected, promoter activity
increased about 2-fold (P,0.05).
INCA1 plays an important role in the regulation of DNA
replication by ING5
Since both ING5 and INCA1 were involved in cell cycle
regulation [7,10,21], we analyzed cell cycle progression with PI
staining by FACS. We first investigated how this interaction
influenced cell cycle distribution in non-synchronized cell lines. In
Inca1
+/+ MEFs with ING5 overexpression, there was an
accumulation of cells in S-phase compared to Inca1
+/+ control
MEFs (P,0.01; Fig. 3A), which was not significant in Inca1
2/2
MEFs (P.0.05; Fig. 3A).
To determine whether S-phase progression was affected, we
focused specifically on the S-phase population using synchronized
cells by starvation for 48 h in 0.1% FCS and release into medium
containing 10% FCS. We used pulsed-labeling with BrdU to
selectively label cells in S-phase. Cells were collected at the
indicated time points after release. The S-phase fraction started to
increase in all four cell lines 8 h after refeeding (Fig. 3B). In
wildtype MEFs with ING5 overexpression, S-phase accumulation
reached its peak at 22 h and decreased to the lowest level at 30 h.
In all other cell lines, S-phase peaked at 18 h and began to
decrease to the lowest points at 26 h (P,0.01). As shown in
Figure 3C, ING5 overexpression in wildtype MEFs induced a
marked delay in progression through S-phase for BrdU-labeled
cells, and the inhibition occurred mainly in early S-phase. These
data indicate that ING5 slows down S-phase progression in an
INCA1-dependent manner.
CDK2 is an important regulator of S-phase progression. We
detected expression of CDK2 in the four cell lines cultured under
normal condition or 0.1% FCS culture medium for 48 h. Since
activation of CDK2 complexes requires phosphorylation of
Thr160, the level of its active form phospho-Thr160 CDK2 was
analyzed. ING5 overexpression decreased both CDK2 expression
Table 1. Genes identified in a yeast two-hybrid system for
INCA1 interaction partners.
Gene Accession No.
1 DAZ associated protein 2 (DAZAP2) BC002334
2 Inhibitor of growth family, member 5 (ING5) NM_032329
3 Ring finger protein 26 (RNF26) BC007534
4 Guanine nucleotide binding protein (G protein),
beta polypeptide 2-like 1
BC032006
5 Ubiquitin-specific protease homolog (UPH) AF153604
6 Chromosome 9 open reading frame 114(C9orf114) BC046133
7 WD repeat domain 85 (WDR85) NM_138778
8 Tripartite motif-containing 26 (TRIM26) BC032297
9 RAB5C, member RAS oncogene family BT019484
doi:10.1371/journal.pone.0021505.t001
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especially at low serum conditions (Fig. 3D). Remarkably,
expression or phophorylation of CDK2 could not be altered by
ING5 in absence of INCA1 at both serum conditions (Fig. 3D).
Taken together, these results showed that overexpression of
ING5 delays S-phase progression and accumulates cells in early S-
phase, with downregulation of CDK2 activity. Notably, these
effects are dependent on the presence of INCA1.
Figure 2. Inhibition of cell growth by ING5 depends on INCA1. (A) Inca1
+/+ and Inca1
2/2 bone marrow cells were retrovirally transduced with
ING5 or empty vector, sorted by FACS, and then subjected to colony formation assays. Data are shown as mean plus standard error of three
independent experiments (*P,0.05 compared to Inca1
+/+ control;
#not significant). (B) Immortalized MEF cells from Inca1
+/+ and Inca1
2/2 were
retrovirally transduced with ING5 or empty vector. After being sorted by FACS, four stably transduced cell lines were established as bulk culture. ING5
overexpression was confirmed by Western blotting with anti-ING5 antibody. (C) Cell lines were cultured in medium containing 10% FCS or 0.1% FCS
and analyzed for proliferation using [
3H]thymidine incorporation. Data are shown as mean plus standard error of three independent experiments
(**P,0.01 compared to Inca1
+/+ control;
#not significant, *P,0.05 compared to Inca1
2/2 control). (D) Inca1
2/2 MEFs were transfected with ING5,
INCA1 or both, and activation of a p53-responsive promoter was analyzed by luciferase assay. ING5 and INCA1 co-transfection led to activation of the
promoter. Data are shown as mean plus standard error of three independent experiments (
#not significant, *P,0.05 compared to control).
doi:10.1371/journal.pone.0021505.g002
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INCA1-dependent way
It has previously been reported that ING5 overexpression
results in increased apoptosis [7]. Overexpression of ING5,
INCA1 or both in MEFs did not induce significant apoptosis
(data not shown). Therefore, we examined whether the interaction
between ING5 and INCA1 affected the sensitivity of cells to
apoptosis-inducing agents such as TNFa, TRAIL and anti-Fas
antibody. TNFa (200 ng/ml) and TRAIL (100 ng/ml) failed to
induce apoptosis in all 4 MEF cell lines described above (data not
shown), while apoptosis was detected when cells were exposed to
Fas antibody (1 mg/ml) for 24 h or 48 h. Overexpression of ING5
in wildtype MEFs caused a dramatically increased apoptotic rates
at 24 h (P,0.05) or 48 h (P,0.01) compared to Inca1
+/+ control
MEFs (Fig. 4). In Inca1
2/2 MEFs, Fas antibody treatment for 24 h
or 48 h only induced apoptosis in control vector cells, but not in
ING5 overexpressing cells, suggesting that ING5 overexpression
renders MEFs resistant to Fas-induced apoptosis in the absence of
INCA1.
To investigate whether Fas expression was affected, we
determined expression of membrane Fas and total Fas by flow
cytometry. ING5 overexpression down-regulated both membrane
and total Fas expression in Inca1
2/2 and Inca1
+/+ MEFs (Figure
S1), which is not consistent with the results of apoptosis, suggesting
that other mechanisms may mediate the process. These results also
indicate that INCA1 plays a key role in this pathological process
for determining cell fate, which is in line with the results we
obtained from colony formation and proliferation assays.
Discussion
INCA1 was found in a yeast triple-hybrid system as a novel
protein to interact with cyclin A1/CDK2 complex [21]. In the
present study, we used a yeast two-hybrid screen system to identify
the interaction partners of INCA1 in bone marrow. The interaction
was verified for all isolated proteins by GST pull-down assays. The
interacting proteins included eight known proteins (DAZAP2,
ING5, RNF26, G protein, UPH, WDR85, TRIM26 and RAB5C)
as well as one protein with unknown function (C9orf114). Among
the interacting proteins, ING5, a new member of Inhibitor of
Growth family, was functionally analyzed. ING5 interacted with
INCA1 and was down-regulated in AML blast cells. We therefore
chose ING5 and studied the interaction between INCA1 and ING5
anditseffectsoncell growthcontrolincludingcolonyformation, cell
proliferation, cell cycle progression, and apoptosis.
It has been reported that overexpression of ING5 in cancer cells
resulted in reduced colony formation efficiency through interact-
ing with P53 and P300 [7]. In our study, we also found that ING5
overexpression could inhibit colony formation of mouse bone
marrow cells, however, this effect existed only in the presence of
INCA1. In Inca1
2/2 MEFs, this inhibitory effect of ING5 was
completely abolished. These results suggest that the interacting
partners of ING5 are important for its functions, and INCA1 is
indispensable for the growth inhibition effect of ING5.
P300 is a member of histone acetyl transferase complexes. By
interacting with P53 and P300, ING5 overexpression could
enhance p53 acetylation at Lys-382 residues, which is involved
in transcriptional activity of p53 [7]. We also observed in Inca1
2/2
MEF cells, that co-transfection of both ING5 and INCA1
increased the activity of a p53-responsive promoter, while ING5
alone increased the promoter activity to a much less extent with no
statistical significance. These data confirmed the results of Harris’s
group [7], though they were obtained from different cell types. In
addition, our results suggest that the p53 transcriptional activation
effect of ING5 is partly dependent on its interaction with INCA1.
Recent study suggest that ING family proteins may play dual
roles, as tumor suppressors or oncogenes, under different cellular
conditions [28]. The current study of proliferation assay with
MEFs revealed that ING5 overexpression inhibited cell prolifer-
ation only in Inca
+/+ MEFs, but not in Inca1
2/2 MEFs, indicating
that ING5 inhibits cell growth in an INCA1-dependent manner.
Unexpectedly, when Inca1
2/2 MEFs were cultured in 0.1% FCS
medium, ING5 overexpression even significantly increased cell
proliferation, showing an oncogenic property. These results
suggest that the two facets of ING5 functions in MEFs could be
affected by INCA1 interaction. It could be speculated that by
interacting with different protein partners, ING5 may function as
a tumor suppressor or an oncogene.
ING5 plays a similar role in apoptosis assay. It has been
observed that ING5 overexpression in cancer cells results in
increased apoptosis, which is p53-dependent [7]. Here we show
that ING5 overexpression enhances anti-Fas antibody triggered-
apoptosis, which is totally dependent on INCA1 presence. INCA1
absence even reverses the apoptosis-enhancing effect of ING5 to
apoptosis resistance. These data further confirm that the growth
suppressive function of ING5 relies on its interaction with INCA1.
By measuring BrdU incorporation, Doyon et al. [10] showed
that ING5 complexes with histone acetyltransferases are important
for DNA replication. ING5 knockdown cells almost completely
lack DNA synthesis, suggesting an essential role of ING5 in DNA
replication. Our results confirmed that ING5 overexpression
increased DNA synthesis and accumulated cells in S-phase. In
addition, ING5 also affects cell cycle progression, especially S
phase. In starvation-synchronized wildtype MEFs ING5 overex-
pression caused a delay in early S-phase. ING5 overexpression
also decreased CDK2 activity only in the presence of INCA1 in
cells cultured in normal medium or 0.1% FCS medium. Based on
these results, it is possible that in addition to promoting replication,
ING5 might play a role in the intra-S-phase checkpoint activation
which may slow the rate of DNA replication [29]. The intra-S
checkpoint is active in normal S-phase, which means some
replication stress occurs in a normal S-phase, not only in damaged
cells. Interestingly, these effects were only observed in wildtype
MEFs, but not in Inca1
2/2 MEFs, indicating that INCA1 plays a
key role in the regulation of S-phase progression by ING5.
However, whether these effects of ING5 on DNA replication and
S-phase progression contribute to its tumor suppressor or
oncogenic functions needs to be further studied.
Figure 3. ING5 delays S-phase progression in an INCA1 dependent manner. (A) BrdU was incorporated to S-phase cell cultures by adding to
the medium 1 h before harvesting. ING5 overexpression accumulated cells in S-phase only in the presence of INCA1. Data are shown as mean plus
standard error of three independent experiments (**P,0.01 compared to Inca1
+/+ control;
# not significant compared to Inca1
2/2 control). (B) Cells
were starved for 48 h in 0.1% FCS and released into medium containing 10% FCS. Cells were collected at different time points after releasing for S-
phase progression analysis. Representative figures of BrdU-FITC and PI staining showed that ING5 overexpression in Inca1
+/+ MEFs has prolonged S-
phase and higher DNA synthesis activity. (C) Line figure clearly revealed the prolonged S-phase in Inca1
+/+ MEFs overexpressing ING5 compared to
the other three cell lines. Data are shown as mean plus standard error of three independent experiments (**P,0.01 compared to the other three cell
lines;
#P.0.05 compared to Inca1
2/2 control). (D) The expression of both CDK2 and its active form (phosphor-Thr160-CDK2) was detected by
western blotting in the four cell lines cultured under normal condition or 0.1% FCS culture medium for 48 h.
doi:10.1371/journal.pone.0021505.g003
Interaction between ING5 and INCA1
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e21505In summary, the current study identified several interacting
partners of the CDK inhibitor INCA1. Our data show that by
interacting with INCA1, ING5 exerts tumor-suppressive function
by inhibiting colony formation and cell proliferation, and increasing
Fas-antibody-induced apoptosis. However, without INCA1, ING5
no longer has anti-proliferative effects, and even functions as an
oncogene as indicated by promoting cell proliferation and
protecting cells from Fas-antibody-induced apoptosis. Mechanisms
underlying the different behaviors of ING5 may include alternate
splicing, post-translational protein modifications and protein-
protein interactions that occur in different cellular contexts. Future
study of ING5 should address these questions.
Materials and Methods
Yeast two-hybrid System
To identify INCA1-interacting proteins, a yeast two-hybrid
(Y2H) screen was performed using the Matchmaker
TM Gal4 two-
hybrid system 3 (Clontech). All experiments were carried out
according to the recommendations of the supplier (Clontech, Yeast
Figure 4. ING5 enhanced FAS antibody-induced apoptosis in an INCA1-dependent manner. MEF cell lines were exposed to anti-Fas
antibody (1 mg/ml) for 0 h, 24 h or 48 h. Apoptosis was detected by AnnexinV-PI staining. Overexpression of ING5 in wildtype MEF increased
apoptosis after 24 h and 48 h. However, in Inca
2/2 MEFs, ING5 overexpression prevented CD95-induced apoptosis. Data are shown as mean plus
standard error of three independent experiments (*P,0.05, **P,0.01, and
#P.0.05 compared to CD95 0 h with each cell line). A representative
figure is shown in the lower panel.
doi:10.1371/journal.pone.0021505.g004
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TM two-hybrid system 3). In
brief, a human bone marrow cDNA library was cloned into the
pGADT7 vector (Clontech). INCA1 served as bait for the library
translation products. Full length human INCA1-cDNA was cloned
into pGBKT7. The plasmids were co-transformed into the yeast
strain AH109 (Clontech). Transformed yeast cells were grown on
high stringency selection plates (-Leu, -Trp, -His, -Ade) with 5-
bromo-4-chloro-3-indolyl-D-galactopyranoside (X-gal). Positive
clones were further confirmed by colony-lift filter assay. Yeast
plasmids were isolated and the cDNA inserts were confirmed by
digestion with restriction endonucleases. Sequences were analyzed
by alignment to the NCBI data bases and 30 genes from the
positive clones were selected for further investigation.
Patient samples, RNA isolation and qRT-PCR
Patient samples were collected from the bone marrow of AML
patients. Written informed consent was obtained from all
individuals. The use of the human material for scientific purposes
was approved by the human ethics committees of the participating
institution. The Ethics comitee full name is: ‘‘Ethik-Kommission
der A ¨rztekammer Westfalen-Lippe und der medizinischen Fakul-
ta ¨t der Westfa ¨lischen Wilhelms Universita ¨t Mu ¨nster’’.
Total RNA was isolated from 10 patients with normal bone
marrow and 59 AML patients at the time of diagnosis using
TRIzol reagent (Invitrogen, Carlsbad, CA). RNA (1 mg) was
reverse-transcribed using random primers and MMLV reverse
transcriptase (Promega, Madison, WI) following the manufactur-
er’s protocol. ING5 mRNA expression levels were analyzed by
real-time quantitative RT-PCR using TaqMan methodology as
described [21]. Expression of the housekeeping gene glyceralde-
hyde-3-phosphate-dehydrogenase (GAPDH) was used to normal-
ize the amount of cDNA between different testis samples [30].
ING5 primer and probe sequences will be provided on request.
Cell Culture and Transfection
Murine Embryonic Fibroblasts (MEF) were established by
trypsinating E12.5 embryos derived from breeding of Inca1
+/2
females and males [22]. Immortalization of fibroblasts was
achieved with the standard 3T3 protocol. COS-7 (simian renal
cells transformed by SV40, ECACC 87021302) cells and murine
embryonic fibroblast (MEF) cells from Inca1
+/+ and Inca1
2/2 mice
were cultured at 37uC and 5% CO2 in Dulbecco’s modified
Eagle’s medium (Invitrogen) supplemented with 10% fetal calf
serum (Biochrom KG, Berlin, Germany), 100 units/ml penicillin,
and 100 mg/ml streptomycin (Biochrom) and 2 mM L-glutamine
(Biochrom). Immortalization of MEFs was obtained following the
standard 3T3 protocol. Inca1 was cloned into pcDNA3.1(+) fused
to enhanced green fluorescent protein (EGFP) (Clontech) as
described previously [21]. pcDNA3.1-ING5 was a kind gift from
Dr. Harris (Laboratory of Human Carcinogenesis, Center for
Cancer Research, National Cancer Institute). COS-7 cells were
transfected using SuperFect
TM (QIAgen, Hilden, Germany)
according to the manufacturer’s protocol, and were used for co-
immunoprecipitation. MEF cells were infected by retroviral
particles (Pinco Expression Vector System; Pharmingen, San
Diego, CA) with Lipofectamine Plus reagent (Invitrogen) accord-
ing to the manufacturer’s instructions.
GST Fusion Proteins and GST Pull-down Assays
Inca1 was cloned in frame into the pGEX-5X-2 plasmid
(Amersham Biosciences) as GST fusion proteins, expressed in
Escherichia coli BL21-DE3, and purified using glutathione-agarose
beads, as described previously [21]. For GST pull-down assays, the
screened gene sequences were expressed and radioactively labeled
with [
35S]methionine in an in vitro transcribed and translated TNT
QuickCoupled Transcription/Translation System (Promega, Ma-
dison, WI), and then were incubated with INCA1 GST-proteins
for 1 h at 4uC. After washing with binding buffer and SDS-PAGE,
the gel was dried and analyzed by autoradiography.
Antibodies, Western blotting and Co-
immunoprecipitation
Radioimmune precipitation lysates (150 mM NaCl, 1% Non-
idet P-40, 0.5% deoxycholic acid, 0.1% SDS, 50 mM Tris-HCl
(pH 8.0)) with Complete EDTA-free protease inhibitor) or the
indicated protein solutions were run on SDS-PAGE gradient gels
(Bio-Rad). Subsequently, proteins were electroblotted onto PVDF
membranes Immobilon-P (Millipore Corp., Bedford, MA), stained
with specific primary antibodies and peroxidase-linked secondary
antibodies (Jackson Immunoresearch Laboratories, West Grove,
PA) and detected with ECL plus (Amersham Biosciences). Primary
antibodies used for Western blot or immunoprecipitation were
anti-actin (Sigma), anti-EGFP (Clontech), and anti-ING5 (Rock-
land Immunochemicals, Inc. PA). For co-immunoprecipitation,
COS-7 cells were co-transfected with expression plasmids of
EGFP-INCA1 and ING5. The cell lysates were precipitated with
anti-ING5 or anti-EGFP antibodies, the bound proteins were
subjected to SDS-PAGE and blotted for EGFP-INCA1 or ING5,
as described previously [21].
Colony Formation Assays
Colony formation assays of primary bone marrows obtained
from Inca1
+/+ and Inca1
2/2 littermates were carried out essentially
as described [31]. All animal experiments were performed with
permission of the local veterinary administration (G15/2005 and
8.87-51.04.20.09-322). The animal welfare comitee/ageny is:
‘‘Landesamt fu ¨r Natur, Umwelt und Verbraucherschutz NRW’’.
For retroviral transduction, the packaging cell line Plat-E was
transfected with the empty vector Pinco or pinco-ING5, and
supernatants were collected every 12 hrs, starting 36 hrs after the
transfection and the viruses were bound to retronectin-coated
plates by centrifugation. Lineage-depleted bone marrow cells were
growth-factor-stimulated overnight, transduced by growth on the
virus-coated retronectin plates there times for 24 hrs and sorted by
FACS for GFP-positivity. 1000 GFP-positive cells per milliliter
methylcellulose were plated. Colony-forming units (CFU) were
counted on day 7.
Establishment of stable cell lines
Immortalized MEF cells from Inca1
+/+ and Inca1
2/2 mice were
transduced with empty pinco vector or pinco-ING5. GFP-positive
cells were sorted by FACS to establish ING5 overexpression MEF
cells lines (Inca1
+/+-ING5 and Inca1
2/2-ING5) and control cells
lines (Inca1
+/+-control and Inca1
2/2-control ).
Promoter Activity and Luciferase Assay
For analyses of INCA1 and ING5 transactivation effects on the
p53-responsive promoter, the consensus sequence of p53-binding
sites was cloned into the pGL3 basic vector 59 of a minimal TK
promoter position to the firefly luciferase gene. Luciferase assays for
promoteractivitywerecarried outessentiallyasdescribed[21]using
the Dual-Luciferase reporter assay system (Promega, Madison, WI).
A Renilla luciferase plasmid driven by a SV40 promoter and the
luciferase reporter and expression construct were used to co-
transfect Inca1
2/2 MEFs with expression vectors containing ING5,
INCA1 or both. The promoter activity was determined as the ratio
of firefly luciferase luminescence divided by Renilla luciferase
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Proliferation assay
MEF cells were seeded into 96 well plates and cultured in 10%
FCS or 0.1% FCS medium. [
3H]-thymidine was incorporated
overnight before cells were lysed. The proliferation rate was
determined as described previously [21]. Results are presented
from three independent experiments.
Cell cycle Analysis
Cells were pulsed by BrdU for 1 hour before cells were collected
by trypsinization at indicated time points. Samples were fixed in
70% ethanol at 4uC overnight. FITC labeled anti-BrdU and
propidium iodide (PI, Sigma) staining was performed. DNA
content was analyzed by flow cytometry with FACScan (Becton
Dickinson, Mountain View, CA, USA) using the CELLQuest
program (Becton Dickinson). Cell cycle distribution was analyzed
by WinMDI software. Data presented are from three independent
experiments.
Apoptosis
Cells were treated with TNFa (200 ng/ml), TRAIL (100 ng/ml)
or anti-Fas antibody (1 mg/ml) for 24 h or 48 h. Both adherent and
non-adherent cells were harvested. The experiment was performed
using the Annexin V-FITC Apoptosis Detection Kit (BD Pharmin-
gen, USA) according to the manual.
Statistical analysis
Data are shown as means plus SD from three independent
experiments if not stable otherwise. Statistical comparisons were
made using students’ t-test. P,0.05 was considered statistically
significant.
Supporting Information
Figure S1 Overexpression of ING5 decreased both
membrane and total Fas expression. The expression of
membrane Fas and total Fas was detected by flow cytometry.
ING5 overexpression down-regulated both the membrane and
total Fas expression in Inca1
+/+ MEFs and Inca1
2/2 MEF cells.
Data are shown as mean plus standard error of three independent
experiments (**P,0.01 compared to control; *P,0.05 compared
to control).
(TIF)
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